Results 171 to 180 of about 172,482 (334)
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
European Journal of Heart Failure, Volume 24, Issue 11, Page 2131-2139, November 2022., 2022 Among patients with new‐onset or worsening heart failure (HF) undergoing optimization of HF medical therapy, dose up‐titration of angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) therapy was associated with lower likelihood of left atrial adverse remodelling (LAAR).Riccardo M. Inciardi, Matteo Pagnesi, Carlo M. Lombardi, Stefan D. Anker, John G. Cleland, Kenneth Dickstein, Gerasimos S. Filippatos, Chim C. Lang, Leong L. Ng, Pierpaolo Pellicori, Piotr Ponikowski, Nilesh J. Samani, Faiez Zannad, Dirk J. van Veldhuisen, Scott D. Solomon, Adriaan A. Voors, Marco Metra +16 morewiley +1 more sourceEarly genetic screening and cardiac intervention in patients with cardiomyopathies in a multidisciplinary clinic
ESC Heart Failure, EarlyView.Abstract Aims
Patients with cardiomyopathies are a heterogeneous group of patients who experience high morbidity and mortality. Early cardiac assessment and intervention with access to genetic counselling in a multidisciplinary Cardiomyopathy Clinic may improve outcomes and prevent progression to advanced heart failure.Chandu Sadasivan, Luke R. Gagnon, Deepan Hazra, Kaiming Wang, Erik Youngson, Jissy Thomas, Anita Y.M. Chan, D. Ian Paterson, Finlay A. McAlister, Tara Dzwiniel, Wayne Tymchak, Susan Christian, Gavin Y. Oudit +12 morewiley +1 more sourceBLITZ‐HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelines
European Journal of Heart Failure, Volume 24, Issue 11, Page 2078-2089, November 2022., 2022 Aims
To assess adherence to guideline recommendations among a large network of Italian cardiology sites in the management of acute and chronic heart failure (HF) and to evaluate if an ad‐hoc educational intervention can improve their performance on several pharmacological and non‐pharmacological indicators.Michele Massimo Gulizia, Francesco Orso, Andrea Mortara, Donata Lucci, Nadia Aspromonte, Leonardo De Luca, Giuseppe Di Tano, Giuseppe Leonardi, Alessandro Navazio, Giovanni Pulignano, Furio Colivicchi, Andrea Di Lenarda, Fabrizio Oliva, on behalf of
BLITZ‐HF Investigators, G. Pajes, A.R. Felici, P. Midi, G. Leonardi, G. Montana, V. Randazzo, E. Guerri, E. Lo Jacono, V. Zanasi, C. Leuzzi, V. Rizzello, A. Battagliese, N. Pagnoni, G. Pulignano, M. Uguccioni, M.D. Tinti, G.M. Frigo, M. Anselmi, E. Zorzi, I. Battistoni, G.P. Perna, L. Prosseda, M. Pulcini, C. Pellizzari, C. Paolini, G. Bardelli, R. Panciarola, B. Bordoni, S. Urbinati, C. Pedone, C. Greco, E.R. Cosentino, C. Borghi, C. Cuccia, L. Caprini, C. Mariani, C. Borghi, E. Benvenuto, M.B. Zisa, G.M. Francese, M.M. Gulizia, M. Bartolotti, M. Marconi, D. Severini, K. Mboumi, E. Capati, F. Venturi, E. Savini, D. Gabrielli, A. Herbst, F. Orso, F. Sani, C. Minneci, E. Gardini, D. Nanni, C. Lirato, F. Piemonte, P. Ameri, M. Canepa, F. Mainardi, R. Ghinazzi, F. Poletti, C. Inserra, S. Arcidiacono, V. Crisci, C.C. De Carlini, S. Maggiolini, F. Napoli, A.G. Versace, I. Di Matteo, A. Sacco, A.F. Giglio, M.G. Cipriani, G. Mombelli, A. Alberti, V. Antonazzo, O. Agostoni, G. Riboni, G. Guazzotti, S. Mazzetti, A. Mortara, L. Montagna, M.G. Perrelli, L. Scelsi, S. Ghio, A. Gualco, C. Opasich, L. Filippucci, A. Burini, I. Puggia, E. Loiudice, G. Iabichella, A. Nicosia, A. Frisinghelli, G. De Angelis, P. Del Corso, F. Marzo, S. Carigi, G. Piovaccari, S. Refice, T. Nejat, S.A. Di Fusco, F. Colivicchi, D. Pini, P. Romano, G. Padula, A. Gigantino, L. Spera, A. Pagliaro, L.L. Piccioni, C. Napoletano, C. Calcagnile, P. Sbarra, D. Belloli, P.C. Sganzerla, M. Merlo, V. De Paris, M. Driussi, D. Miani, C.A. Gianonatti, L. Moretti, G. Licciardello, V. Palmieri, P. Costa, S. Zingaro, L. Tedesco, A. Iacovoni, M. Liotino, A. Ravera, A. De Castro, G. Rossetti, M. Corda, D. Armata, G. Vianello, E. Pelissero, G. Ruberti, S. D'Orazio, C. Pedrinazzi, D. Robba, A. Carbone, F. De Cian, A. Fucili, F. Grossi, N.D. Brunetti, C. Minoia, M. Pernigo, S. Costa, L. Esposito, G. Senatore, P. Pelaggi, R. Poddighe, E. Zanelli, L. Salvini, G. Galati, A. Zanocco, M. Cannillo, A. Vincenzi, M.A. Losi, L. Caliendo, V. Orrù, E. Carluccio, L. Garritano, E. Garelli, R. Poletti, M. Taglioli, G. Scopelliti, M. Lo Presti, C. Gardini, S. Iosi, C. Tota, M. Mancone, C. De Matteis, F. Rusconi, M.A. Ammirati, G. Cicia, S. Meloni, F. Menozzi, A. Cafro, M. Ribezzo, I. Parrini, S. Giacomelli, G. Russo, F. Morandi, F. Sturniolo +197 morewiley +1 more sourceRelaxin mimetic in pulmonary hypertension associated with left heart disease: Design and rationale of Re‐PHIRE
ESC Heart Failure, EarlyView.Abstract Aims
Despite receiving guideline‐directed medical heart failure (HF) therapy, patients with pulmonary hypertension associated with left heart disease (PH‐LHD) experience higher mortality and hospitalization rates than the general HF population.Marcin Ufnal, Kathleen Connolly, Marcus Millegard, Elena Surkova, Marco Guazzi, Diana Bonderman, Justin Ezekowitz, Finn Gustafsson, Michał Ciurzyński, Raquel López Vilella, Tariq Ahmad, Roy Gardner, Pavel Jansa, Sandra van Wijk, Koichiro Kinugawa, Erik Björklund, Zhi‐Cheng Jing, Stephan Rosenkranz +17 morewiley +1 more sourceUse of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence
European Journal of Heart Failure, Volume 24, Issue 11, Page 2185-2195, November 2022., 2022 Patients with heart failure and chronic kidney disease are less likely to receive and persist on guideline‐recommended medical therapies. Aim
Half of heart failure (HF) patients have chronic kidney disease (CKD) complicating their pharmacological management.Roemer J. Janse, Edouard L. Fu, Ulf Dahlström, Lina Benson, Bengt Lindholm, Merel van Diepen, Friedo W. Dekker, Lars H. Lund, Juan‐Jesus Carrero, Gianluigi Savarese +9 morewiley +1 more source